Prospective study of markers of hemostatic function with risk of ischemic stroke

Circulation

Volumn 100, Issue 7, 1999, Pages 736-742

  Folsom, Aaron R ^a   Rosamond, Wayne D ^b   Shahar, Eyal ^a   Cooper, Lawton S ^c   Aleksic, Nena ^d   Nieto, F Javier ^e   Rasmussen, Mandy L ^a   Wu, Kenneth K ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b IL   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Hemostasis; Ischemia; Stroke

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8C; FIBRINOGEN; PROTEIN C; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; STROKE;

EID: 0033578475     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.7.736     Document Type: Article

References (31)

1. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Mean Study. Lancet. 1986;2:533-537.
2. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
3. Kannel WB, WoIfPA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258: 1183-1186.
4. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279: 1477-1482.
5. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARlC) Study. Circulation. 1997;96:1102-1108.
6. Jansson J-H, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J. 1991;66:351-355.
7. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA, Leukocytes and the risk of ischemic diseases. JAMA. 1987;257:2318-2324.
8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
9. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
10. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-242.
11. Smith FB, Lee AJ,l Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1997;17: 3321-3325.
12. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med. 1992;117:371-375.
13. Prentice RL, Szatrowski TP, Kato H, Mason MW. Leukocyte counts and cerebrovascular disease. J Chronic Dis. 1982;35:703-714.
14. Gillum RF, Ingram DD, Makuc DM, White blood cell count and stroke incidence and death: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1994;139:894-902.
15. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ. von Willebrand factor and factor VIIIc in acute cerebrovascular disease: relationship to stroke subtype and mortality. Thromb Haemost. 1997;77: 1104-1108.
16. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129: 687-702.
17. Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC hemostasis study, I: development of blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost. 1989;61:15-19.
18. Atherosclerosis Risk in Communities Study Manual 9: Hemostasis Determinations. Chapel Hill, NC: National Heart, Lung, and Blood Institute of the National Institutes of Health, Collaborative Studies Coordinating Center, University of North Carolina; 1987.
19. Chambless LE, McMahon R, Wu K, Folsom A, Finch A, Shen Y-L. Short-term intraindividual variability in hemostasis factors: the ARIC Study. Ann Epidemiol. 1992;2:723-733.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
21. Baecke JAH, Burema J, Frijters JER. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36:936-942.
22. Crow RS, Prineas RJ, Rautaharju P, Hannan P, Liebson PR. Relation between electrocardiography and echocardiography for left ventricular mass in mild systemic hypertension (results from Treatment of Mild Hypertension Study). Am J Cardiol. 1995;75:1233-1238.
23. Rosamond WD, Folsom AR, Chambless LE, Wang C-H, McGovern PG, Howard G, Cooper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-743.
24. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
25. Meade TW, North WRS, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovie M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980;1:1050-1054.
26. Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost. 1992;67:594-599.
27. Blann A. von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci. 1993;50:125-134.
28. Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1995;15:1269-1279.
29. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 1991;83: 836-844.
30. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
31. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb. 1993;13:1829-1836.